Oki Mark K 4

What Happened Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, was granted a derivative award for 180,000 shares on January 28, 2026. The Form 4 reports the award as acquired at $0.00 per share (no cash paid at grant). This is a grant/award (not a market purchase or sale) and does not represent an immediate sale of shares.

Key Details

• Transaction date: 2026-01-28; Form 4 filed 2026-01-30 (filed timely).
• Transaction type/code: Award/Grant (A), derivative security.
• Amount: 180,000 shares; reported price $0.00 (acquired value $0 in filing).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote on vesting: 25% vests on the first anniversary of the grant date, then the remainder vests in substantially equal monthly installments over the following 36 months, subject to continued service.

Context This was a time-vesting derivative award (likely RSUs or similar) subject to continued employment; the award vests over four years and is not an immediate sale or exercise. Such grants are typically part of compensation/retention plans and do not by themselves indicate buying or selling intent in the open market.